Rutgers New Jersey Medical School

Running trials

• Enrolling by invitation

  Mail-in HPV Screening Program in NJ

  NCT07575217· Rutgers, The State University of New Jersey· Source

• Recruiting

  Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

  NCT07195734· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  NCT07198074· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe

  NCT06825897· Santiago Ortega Gutierrez· Source

• Recruiting

  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

  NCT07061977· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  HOPE Against Cancer Recurrence in HCC

  NCT06717919· Phase 4· Philipp Dutkowski· Source

• Active, not recruiting

  A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

  NCT07044297· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain

  NCT06374238· University of Pittsburgh· Source

• Active, not recruiting

  A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

  NCT06812325· Phase 3· Viridian Therapeutics, Inc.· Source

• Active, not recruiting

  Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

  NCT06500455· Phase 3· NRG Oncology· Source

• Active, not recruiting

  An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06625398· Phase 3· Viridian Therapeutics, Inc.· Source

• Active, not recruiting

  An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

  NCT06625411· Phase 3· Viridian Therapeutics, Inc.· Source

• Recruiting

  Liver Transplantation in Intrahepatic Cholangiocarcinoma

  NCT06140134· Rutgers, The State University of New Jersey· Source

• Recruiting

  Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  NCT05946213· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

  NCT06101342· Phase 2· Gilead Sciences· Source

• Active, not recruiting

  Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy

  NCT05591118· Phase 3· NYU Langone Health· Source

• Recruiting

  Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  NCT05624996· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Assessment of Combined CCM and ICD Device in HFrEF

  NCT05855135· Impulse Dynamics· Source

• Recruiting

  Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

  NCT05432804· Phase 1/2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Intravesical BCG vs GEMDOCE in NMIBC

  NCT05538663· Phase 3· ECOG-ACRIN Cancer Research Group· Source

• Recruiting

  Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

  NCT05327686· Phase 2· NRG Oncology· Source

• Active, not recruiting

  Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

  NCT05256225· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

  NCT05172245· Phase 1· National Cancer Institute (NCI)· Source

• Recruiting

  Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

  NCT05174169· Phase 2/3· NRG Oncology· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

  NCT05095376· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

  NCT05050084· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer

  NCT04871516· Rutgers, The State University of New Jersey· Source

• Active, not recruiting

  Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

  NCT04559139· Phase 2/3· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

  NCT04513717· Phase 3· NRG Oncology· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

  NCT04544449· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  NCT04251052· NRG Oncology· Source

• Active, not recruiting

  NCI COVID-19 in Cancer Patients, NCCAPS Study

  NCT04387656· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

  NCT04134260· Phase 3· NRG Oncology· Source

• Active, not recruiting

  Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

  NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

  NCT03907488· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

  NCT03811015· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

  NCT04253483· Phase 2· Rutgers, The State University of New Jersey· Source

• Active, not recruiting

  Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

  NCT03765918· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

  NCT03180268· Phase 3· NRG Oncology· Source

• Recruiting

  Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  NCT02734537· Phase 2· ECOG-ACRIN Cancer Research Group· Source

• Active, not recruiting

  Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

  NCT02466971· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

  NCT01708954· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

  NCT01220583· Phase 2· Radiation Therapy Oncology Group· Source

• Active, not recruiting

  Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

  NCT01142388· Phase 2· National Cancer Institute (NCI)· Source

Showing 50 of 54.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Head and neck cancer3 recruiting
• Cervical cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Glioblastoma1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting

Closed trials

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

  NCT06384547· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301

  NCT06179875· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06021054· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

  NCT05176639· Phase 3· Viridian Therapeutics, Inc.· Source

• Recruiting

  Assessment of CCM in HF With Higher Ejection Fraction

  NCT05064709· Impulse Dynamics· Source

• Completed

  A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

  NCT05198804· Phase 1/2· K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  Using MASL to Combat Oral Cancer

  NCT04188665· Early phase 1· Rowan University· Source

• Completed

  Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

  NCT04037254· Phase 1/2· NRG Oncology· Source

• Completed

  Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites

  NCT03451292· Phase 3· Grifols Therapeutics LLC· Source

• Completed

  First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

  NCT02675465· Phase 1/2· Amicus Therapeutics· Source

• Completed

  Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)

  NCT02119702· Harvard School of Public Health (HSPH)· Source

• Completed

  Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

  NCT01101451· Phase 3· GOG Foundation· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· National Cancer Institute (NCI)· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women

  NCT01310023· Harvard School of Public Health (HSPH)· Source

• Completed

  Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737· Phase 3· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Tuberculosis54 works · 0 trials
• Spinal cord injury32 works · 0 trials
• Deep vein thrombosis and pulmonary embolism28 works · 1 trial
• Alopecia areata9 works · 0 trials
• Duchenne muscular dystrophy6 works · 0 trials
• Lyme disease4 works · 0 trials
• Dermatomyositis and polymyositis (myositis)4 works · 0 trials
• Barrett's oesophagus3 works · 0 trials